Maplight Therapeutics Inc.
06/24/2026 | Press release | Distributed by Public on 06/24/2026 05:12
Proxy Results (Form 8-K)
| Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
On June 23, 2026, MapLight Therapeutics, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders considered two proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2026 (the "Proxy Statement"). Of the 42,610,079 shares outstanding as of the record date, 36,883,750 shares, or approximately 86.56%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.
Proposal No. 1: Election of three nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:
|
Name |
Votes For | Votes Withheld | ||||||
|
Martin Babler |
31,424,194 | 3,575,737 | ||||||
|
Troy Cox |
34,979,012 | 20,919 | ||||||
|
George Pavlov |
34,220,342 | 779,589 | ||||||
Broker Non-Votes: 1,883,819
All nominees were elected.
Proposal No. 2: Ratification of the selection of RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows:
| Votes For | Votes Against | Abstained | ||||||||||
|
Ratification of selection of RSM US LLP |
36,859,217 | 22,332 | 2,201 | |||||||||
Broker Non-Votes: 0
Maplight Therapeutics Inc. published this content on June 24, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 24, 2026 at 11:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]